Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (November 2019)
25 slides from Inspiremd's investor presentation, Nov 12, 2019
Slide 1: InspireMD
inspirelD InspireMD James Barry, Ph.D. President and CEO | November 2019
Slide 2: Disclaimers
Disclaimers This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," “plans,” "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements ar
Slide 3: About InspireMD
About InspireMD InspireMD is a commercial-stage medical device company focused on stroke prevention for patients with carotid artery disease and other vascular diseases utilizing an integrated embolic protection technology COMPAI TECHNOLOGY PRODUCTS NYSE AMER: NSPR Proprietary MicroNet™ Commercial:
Slide 4: Company Highlights
Company Highlights J Enabling a paradigm shift (CAS) in the treatment of carotid artery disease and stroke prevention CGuard™ EPS | Breakthrough platform: Highly differentiated, with strong support from leading clinicians | MicroNet™ technology that is elegantly simple, propriety and easily leverage
Slide 5: Stroke is the Second Biggest Cause of Death
Stroke is the Second Biggest Cause of Death An estimated 15 million people suffer from stroke annually? 6.2 million deaths! 5 million people left permanently disabled? $34 billion associated with stroke management in the US alone? * ~ 85% ofall strokes are ischemic strokes, which result from a lack
Slide 6: Unmet Need: A Safer Technology for Stroke Prevention in CAD
Unmet Need: A Safer Technology for Stroke Prevention in CAD Surgery vs. Carotid Artery Stenting Carotid Endarterectomy (CEA) Filter Protected Stenting (CAS) “Gold standard”’, but... Patient friendly, long-term durability’, Invasive; risk of surgical complications Non-Invasive; risk of complications
Slide 7: Current Treatments for Carotid Artery Disease
Current Treatments for Carotid Artery Disease Surgery (Carotid Endardarectomy) (CEA) vs. Conventional Carotid Stents (CAS) CREST Death Stroke Any Major ipsilateral Major nonipsilateral} Minor ipsilateral Minor nonipsilateral Myocardial infarction Any periprocedural stroke or postprocedural ipsilater
Slide 8: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents, depending on plaque morphology/symptomatic status and stent type. The consequence is cerebral embolization, either directly or via additional thrombus formation.
Slide 9: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit to Stroke Post-intervention showing successful opening of the occluded carotid artery with conventional stenting and an MRI showing multiple micro-infarcts (obstructions) post- procedure due to liberation of embolic particles. Pre-intervention showing 90%
Slide 10: A Billion Dollar Market Opportunity
A Billion Dollar Market Opportunity Carotid procedures today are Carotid procedures tomorrow could be primarily surgical mostly minimally invasive with CGuard™ 20% of Market 100% of Market 80% of Market CEA —BCAS =CAS MicroNet™ covered stents could become the Gold Standard 2.2M diagnosed with caroti
Slide 11: The InspireMD Solution: CGuard™ EPS
The InspireMD Solution: CGuard™ EPS Conventional C: id Sten CGuard™ E Plaque protrusion may lead to early and ate distal embolization Debris y Arterial ~S pro 2" + The MicroNet™ permanently covers plaque and stops “debris” from passing through the mesh. + Ultrathin PET mesh made of a single 20 micro
Slide 12: The InspireMD Solution: CGuard™ EPS
The InspireMD Solution: CGuard™ EPS No plaque coverage - leading to plaque protrusions or The MicroNet™ permanently covers plaque and prolapse passing into the vessel lumen prevents “debris” from passing through the mesh. Conventional Carotid Stent MicroNet mesh preventing prolapse Yoshimura, et al
Slide 13: Positive CGuard™ EPS Clinical Experience
Positive CGuard™ EPS Clinical Experience CARENET al Trial (2014) 30 Patient Safety and Efficacy clinical trial Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to historical n
Slide 14: Analysis of Published Carotid Stent Trial Data
Analysis of Published Carotid Stent Trial Data Comparative analysis of the carotid stent data available in public domains ( journal publications plus congress presentations published on-line ) Cumulative Incidence of Death/Stroke/MI @ 30 days plus 1-year ipislateral stroke rate . Conventional single
Slide 15: Analysis of Published Next Generation Carotid Device Trial Data
Analysis of Published Next Generation Carotid Device Trial Data* Patient-level meta-analysis Dual-layer stents 556 patients / 4 trials (both symptomatic and asymptomatic) ** 1-yea r data Cumulative results at one year according to Stent Platform 6) @cguard mroadsaver ts = = | Stroke Death stroke *De
Slide 16: CGuard™ EPS vs Conventional Stents and Surgery
CGuard™ EPS vs Conventional Stents and Surgery ¢ CGuard™ EPS has a superior profile versus historical data on both conventional carotid stents and surgery CGuard™ is a next-generation stent supported by a strong and growing body of clinical data 7 completed clinical trials and 4 ongoing trials *NOTE
Slide 17: A Leading Vascular Surgeon's View
A Leading Vascular Surgeon’s View tl “The CGuard™, in comparison to other [carotid] stents, even in comparison to other mesh covered stents, is a very easy to use device. Very simple, you take it off the shelf and you use it and that’s it.” “Patient risks associated with stenting using CGuard™ are f
Slide 18: Commercial Strategy
Commercial Strategy Transition current users of carotid stents to C6uard™ EPS Continued communication of CGuard™ EPS clinical data Continue to support investigator initiated clinical registries Continue to develop network of KOLs, broaden centers of excellence to multiple clinical disciplines Expand
Slide 19: CGuard™ EPS Product Development
CGuard™ EPS Product Development IDE FDA submission for CGuard™ EPS July 2019 + Additional request from FDA for information in support of application August 2019 + Working closely with FDA to resolve additional requests for information * Critical step in commencing human trial in the USA + CGuard con
Slide 20: Addressable Stroke Prevention Device Market
Addressable Stroke Prevention Device Market 3) IQ % IQ - O O O O 0 13mn people 2.2mn people ~600,000 received Untapped market: At Plus roughly globally with high with HGS surgical/stent least 1.6mn patients 10mn people who grade carotid diagnosed treatment could be helped by are undiagnosed stenosis
Slide 21: Intellectual Property Portfolio
Intellectual Property Portfolio PATENT RIGHTS ISSUED ALLOWED PENDING USA 13 2 6 Rest of World 47 0 ag: Proprietary platform technology supported by a robust intellectual property portfolio Continue to strengthen and broaden patent protection globally to enable future pipeline products inspireMD —
Slide 22: Leadership
Leadership Significant track records of success es Barry, Ph.D Boston, President and CEO Scientific (Pfizer a! Shore Pricer Tow Fie Sle Swen Oveartiow , Cordis. @ussvary ee ae Sol Barer, Gee Tra Special Advisor to the Board {BARONET ROASTS November 2019 | 22 inspireMD
Slide 23: Summary Financials
Summary Financials NYSE AMERICAN NSPR Stock Price (10/31/19): $1.13 Average last month daily trading volume: 242 K Shares outstanding (10/31/19): 3.6 M Shares outstanding including full conversion of preferred shares and prefunded warrants 49M (10/31/19): Market capitalization including full convers
Slide 24: Summary
Summary Q SQ ey — Td Focused on the deadly and catastrophic problem of stroke that is estimated to cost the healthcare system more than $34BB annually in the US alone The current addressable market for CGuard ™ EPS is estimated to be $1BB with the potential to further expand into the 1.6MM patient p
Slide 25: inspireMD
inspireMD